Efficacy and safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense: a multicentre,... (Projects)
https://www.swisstph.ch/en/projects/project-detail/project/efficacy-and-safety-of-fexinidazole-in-patients-with-human-african-trypanosomiasis-hat-due-to-trypanosoma-brucei-rhodesiense-a-multicentre-open-label-clinical-trial
A vector-borne parasitic illness, human African trypanosomiasis (HAT), also known as sleeping sickness, is usually fatal without treatment. The less prevalent form, T.b. rhodesiense (r-HAT), is concentrated
Accelerating towards <em>P. vivax</em> elimination with a novel serological test-and-treat strategy: a modelling case study in Brazil (Publications)
INTERPRETATION: Modelling predicts that mass campaigns with PvSeroTAT are predicted to reduce P. vivax parasite prevalence across a range of transmission settings and require fewer resources than MDA. In combination
Thousands of Visitors Attended Swiss TPH Open House in Allschwil - The Former "Tropeli" Celebrates its 80th Anniversary (News)
https://www.swisstph.ch/en/news/news-detail/news/thousands-of-visitors-attend-swiss-tph-open-house-in-allschwil-the-former-tropeli-celebrates-its-80th-anniversary
health Visitors had the opportunity to conduct experiments in the teaching laboratory, discover parasites under the microscope and learn how infectious diseases such as malaria and tuberculosis are combated
Autumn Semester Starts for Students at Swiss TPH (News)
https://www.swisstph.ch/en/news/news-detail/news/autumn-semester-starts-for-students-at-swiss-tph
aims to understand the mechanisms through which poverty-related infections – such as bacteria and parasites – cause disease. Knowledge gained from studying these and other aspects of infection biology provides
Largest Clinical Trial in Africa to Treat COVID-19 Cases is Launched in 13 Countries (News)
https://www.swisstph.ch/en/news/news-detail/news/largest-clinical-trial-in-africa-to-treat-covid-19-cases-is-launched-in-13-countries
options being explored by ANTICOV are medicines currently used to treat malaria, HIV, hepatitis C, parasitic infections, and certain cancers. About the consortium Major funding for the ANTICOV consortium is
A Tireless Leader (Page)
https://www.swisstph.ch/en/news/20160601-a-tireless-leader
environment certain projects may wither, but the plant must always be able to produce new buds. Parasites, People and Health Systems New drugs, vaccines and diagnostics: all possible means will have to [...] Basel, and earned his PhD in 1980 with a thesis on the cultivation of Trypanosoma, the protozoan parasites that cause African sleeping sickness. From 1981 to 1984, he successfully led the Swiss Tropical
SumayaVac-1: Clinical Trial for New Malaria Vaccine (Page)
https://www.swisstph.ch/en/about/med/clinical-operations/sumayavac-1-clinical-trial-for-new-malaria-vaccine
to assess the vaccine's safety and its ability to generate an immune response against the malaria parasite. Forty participants split into two groups receive three doses, approximately one month apart, of [...] Lipid A Adjuvant-Stable Emulsion). The vaccine simultaneously targets the two crucial stages of the parasite’s infectious cycle, the liver and the blood stage. The study was initiated in August 2023 and the
Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in... (Publications)
and placental malaria (defined as deposition of malaria pigment in the placenta with or without parasites) after different treatments of uncomplicated falciparum malaria were assessed by mixed-effects logistic
Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of <em>Plasmodium falciparum</em> malaria (Publications)
HDAC inhibitors were screened for anti-malarial activity, and the best candidate was profiled in parasite-killing kinetics, growth inhibition of sensitive and multi-drug resistant (MDR) strains and against
Egg excretion indicators for the measurement of soil-transmitted helminth response to treatment (Publications)
infections. However, with programs expanding, drug pressure potentially selecting for drug-resistant parasites increases. While monitoring anthelmintic drug efficacy is crucial to inform country control program
